about
The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms.Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008.Evaluation of exposure-specific risks from two independent samples: a simulation studyQuetiapine versus trazodone in reducing rehospitalization for alcohol dependence: a large data-base study.Cross-calibration and comparison of variability in 2 bone densitometers in a research setting: the framingham experience.A prospective assessment of mortality in chronic spinal cord injury.Durable improvements in prostate cancer screening from online spaced education a randomized controlled trial.Risk factors for chest illness in chronic spinal cord injury: a prospective studyImpact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.Daily step count predicts acute exacerbations in a US cohort with COPD.A SAS macro for a clustered logrank test.Association between sclerostin and bone density in chronic spinal cord injuryDeterminants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injuryMatrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcificationDeterminants of lung volumes in chronic spinal cord injuryA SAS macro for a clustered permutation test.A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system.A comparison of statistical approaches for physician-randomized trials with survival outcomes.Protective effect of total and supplemental vitamin C intake on the risk of hip fracture--a 17-year follow-up from the Framingham Osteoporosis Study.Foot Type Biomechanics Part 2: are structure and anthropometrics related to function?Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients.Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women.Association of elevated alanine aminotransferase with BMI and diabetes in older veteran outpatients.Effect of treating erectile dysfunction on management of systolic hypertension.High-normal blood pressure progression to hypertension in the Framingham Heart Study.Longitudinal change in FEV1 and FVC in chronic spinal cord injury.Dual energy x-ray absorptiometry of the distal femur may be more reliable than the proximal tibia in spinal cord injury.Longitudinal risk factors for intimate partner violence among men in treatment for alcohol use disorders.Statin use and fracture risk: study of a US veterans population.Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.Genome screen for quantitative trait loci contributing to normal variation in bone mineral density: the Framingham Study.Mapping of quantitative ultrasound of the calcaneus bone to chromosome 1 by genome-wide linkage analysis.Technetium-99m sestamibi tomography in patients with spontaneous chest pain: correlations with clinical, electrocardiographic and angiographic findings.Epidemiology of sudden coronary death: population at risk.Incidence, precursors and prognosis of unrecognized myocardial infarction.Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.Risk factors for central serous chorioretinopathy: a case-control study.Anticoagulant use for atrial fibrillation in the elderly.Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population.
P50
Q30881322-B45BC074-3FE3-4979-B8F3-D4B76D94A321Q33403528-DE015373-ADBC-4A6F-AA74-8D5FDDCA5214Q33617167-7D086C0F-BB54-42A2-A4F6-D5525599AD55Q33786260-CA181EC1-0EB8-4606-B12E-49903B58AFDFQ33964947-396CCF55-6AD9-4503-A3C9-D88D66FEBCC7Q34015355-698B59E5-E3EF-4BD6-B763-94E5DC7F2C06Q34162881-82B16368-1E37-45BB-A841-019959DECBA4Q34362836-A63BB1A0-B7A0-4605-84A6-4585734251B7Q34493241-FFA8D182-AFC8-4D75-B852-662801938E17Q34588697-FCFFBA3D-CF3F-49EC-9B27-92763E793B80Q34673119-7D49ECDA-B06E-40E0-BBCA-E95FBF55681AQ35118751-926286B1-5710-44E3-88AD-E69CE14DA842Q35782783-E5FE336C-ECED-4388-B715-CFFD5BAEA9FBQ35851133-71E5AC3A-CB3E-440C-9B1C-EB580351183BQ36925289-E6EA6C0D-1D64-4455-8DDB-1F9598733560Q37109900-5266EA2C-E148-4D5A-A20A-ED38BA4E88E8Q37171589-B3ACD5B0-FFAB-4BEF-967D-0470A1BB0DD2Q37309182-FB0160F7-1561-43EF-A5A5-614A7300C688Q37361203-C450B36A-73DB-4906-BA45-98A7DBF756BDQ37396848-2BB620C4-8AA1-4C14-A5EB-39EF10DC4ABCQ37427564-9B6899D6-0876-4703-ADC8-7EF7B4EB322EQ38445121-C0A0FE1E-B363-4B32-B02E-1B0DC080E762Q38522167-AF54DA1F-1FF1-4C9B-BCD7-43DBC9B14CB8Q39827922-A1FE163F-3711-4208-AEA3-C4D4FC26E3D2Q40189477-FAD3CB64-429A-4377-B442-4F42695682E6Q41167142-17D172CE-0A62-44F7-B11C-B9D3D356692AQ42067438-07C57BE9-D50C-4044-9425-7E1802FDBDAFQ42132547-95813184-2FA3-4677-9BE8-B743D6F4C3B9Q42855777-197A9984-56E7-48FA-BECC-E4337FA763E7Q43433476-1CC8C685-7DA4-4AAD-8A95-9DBB6FAA8915Q43930110-6CE15104-ECCE-4F25-8ADE-58A039FD1016Q44125439-7DF3892C-BA2F-44A0-8111-EF3AEC36E87FQ44178324-6BAE965A-886C-4FD2-8438-7D66FDB8038CQ44229802-4AD5C826-E0AA-4546-8B4A-BD4DDDDC4178Q44455844-E8291C5C-FA05-408D-A710-E42915F3E816Q44563707-3C41FBCB-39CE-43DC-8C03-6FE210060085Q44776229-E27DC11C-5A19-45C9-818B-974DA24C38ABQ44798798-C0135C71-A232-4021-965B-35EF47BE4EFEQ44946325-F99BE243-82A4-4C31-A278-58340F78B1ADQ45023002-DD279FAC-A38D-4450-AB10-62F3E64E8E47
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David R Gagnon
@ast
David R Gagnon
@en
David R Gagnon
@es
David R Gagnon
@nl
David R Gagnon
@sl
type
label
David R Gagnon
@ast
David R Gagnon
@en
David R Gagnon
@es
David R Gagnon
@nl
David R Gagnon
@sl
prefLabel
David R Gagnon
@ast
David R Gagnon
@en
David R Gagnon
@es
David R Gagnon
@nl
David R Gagnon
@sl
P106
P21
P31
P496
0000-0002-6367-3179